Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting find Dr. thank you for sharing :
On January 4, 2007, the SEC charged Defendant Joseph Spiegel of Buyersstrike with securities fraud in connection with his activity when he was a portfolio manager for Spinner Global Technology Fund, Ltd. (“SGTF”), a $200 million hedge fund. See Complaint, SEC v. Joseph J. Spiegel
https://www.sec.gov/litigation/complaints/2007/comp19956.pdf
(Jan. 4, 2007).
According to the SEC Complaint, Spiegel “engaged in an unlawful trading scheme . . . in violation of the antifraud and registration provisions of the federal securities laws."
Why would anybody take him seriously or think he has a shred of credibility? His attacks against CytoDyn are not journalism, they are hit pieces coordinated with a network of short sellers.
Spiegel has been engaging in a fraudulent scheme to profit from illegal and manipulative short selling in CytoDyn’s stock. He does so by coordinating the publication of false and misleading “hit pieces,” masquerading as stock “research” articles, with manipulative trading and quoting activity in CytoDyn’s stock. Spiegel conspires to drive down the price of stock by timing the publication of false and misleading hit pieces with illicit, manipulative trading tactics and quoting activity, including “naked” short sales.
Short sellers like Spiegel are stock traders who sell stock that they do not own to make a profit when the price of a stock goes down. In brief, a short seller locates stock to borrow, sells it for the current market price, and then hopes the price of that stock will decline so he can purchase it in the open market at a cheaper price before returning it to the borrower.
A short seller is required to locate stock to borrow before selling it to ensure that he has a reasonable belief that the stock can be delivered on a specific date. While short selling itself is not illegal, “naked short selling”—selling stock short without first borrowing shares—is plainly illegal under the federal (and many state) securities laws. Naked short selling is sometimes coupled with efforts to fraudulently manipulate the market to drive down the stock price because short sellers need to be certain that the price of the stock will decrease. Most commonly, these efforts take the form of disseminating false negative information about the company to the investing public. If the short seller successfully convinces investors that the company represents a worthless investment, plummeting the company’s stock price, the short seller can walk away with significant profits, while the company’s financial well-being and reputation are severely and irreparably damaged. This type of fraudulent scheme has been an unfortunate element of the public stock markets for decades.
With the rise of the Internet and the advent of social media, short selling—and attendant market manipulation—has developed into a complex, highly sophisticated enterprise. Once a short seller establishes a short position (i.e., once he locates shares to borrow and sells a stock), a network of individuals goes to work, writing, publishing, and promoting what appear to be legitimate works of journalism aimed at exposing negative facts about a company to the investing community, but are in fact complete fabrications. The conspirators benefit from the anonymity permitted by Internet-based publishing, and their “hit pieces” reach a vast audience almost instantaneously by linking to the articles on sites like Twitter and Facebook.
In conjunction with disseminating false or misleading negative information, short attackers engage in a host of deceptive and illegal trading practices that are designed to artificially manipulate stock prices. These tactics include “naked short selling,” “spoofing,” “layering” and “wash trades,”—all of which are plainly illegal under the federal (and many state) securities laws.
just curious, not sure if this information is available, but are the court battles done? Settlements paid? If they aren't I would not expect new ownership to relist or start up operations either. I'm no legal expert by any means but if they prematurely started up (meaning get the trials started, relisting, etc) without the final final settlements completed, could the former ownership try and get a piece of any increase value of the company as a result of the new mgmt efforts?
Big Pharma has a whole group dedicated to publication planning. Usually for scientific data to get published in legit peer reviewed journals, but also have connections with all publications. In addition, you are dealing with the ad agencies that support the brands of these companies and usually are the ones organizing the ad spend and where it goes. Between these two groups, you can bet, BP has influence on what gets published by who, and when.
It does sound familiar which is why I purchased front row tickets to his next money show presentation. This guy is brilliant.
Great post thank you
Wonder what Dan's secret to clean living is?
Couldn't agree with you more. It's not a vaccine but imagine being able to admin Leron after initial diagnosis or a few days in. It will give people hope and maybe, just maybe, keep them out of the hospital vs. what we are seeing now.
Pharma has folks internally that focus on publication planning as part of their responsibility. In essence, get the data published so that we can then cite it but also, buy reprints for our field sales folks, and med affiars teams when requests come in. On the vendor side there are folks who do this all day on behalf of pharma clients. Usually, these pub planning/med communication folks, have ties at these major publishing houses and have influence on what gets published and when. Go to this site and look up leronlimab
https://pubmed.ncbi.nlm.nih.gov/
For anyone still questioning why CYDY called out safety data first in the first Covid trial:
https://www.pm360online.com/small-drug-features-may-have-big-value-in-the-covid-world/
Dan's reaction when he checks his bank account and realizes he could have had $420MM in CVBT/VT shares
This is irritating. Like having ex-CEO of Goldman's run the SEC. But it is some of the stuff a small company has to battle sometimes.
https://beta.firstwordpharma.com/story/5063467
Thank you!
Wish we could have made money by shorting his marriage
I'm wondering in the case of Covid trial if it's more important to establish safety first given all the underlying health problems maybe attributed to the enrolled patients even if they are mild/moderate, you know the doctor's oath of first do no harm so to speak. And if that's the case and the safety data could be retrieved sooner than the efficacy data, then why not tout it. I think there should have been more of "heads up" that this would be the case; I think we were led to believe top line results meant safety/efficacy and everything else. We also have a passionate CEO who is focused on saving lives vs. share price ---right now. That could change but I have heard him say in the past that sometimes saving lives is more important than share price----I'm paraphrasing and obviously it's not a popular position to have when you have many investors who have been waiting for this.
Folks I want this just as bad as anyone but clinical trials require patience I've worked in the industry for over 20 years and the one thing you can't rush is clinical trial results. Just my opinion.
Living in a van down by the river?
Yep and wasn't that around the time Tamiflu( owned by Roche but developed by Gilead which gave them royalties) was the drug of choice for H1N1 or SARS or something like that?
https://www.biospace.com/article/releases/roche-pays-a-href-company_profile-aspx-companyid-1394-b-gilead-sciences-b-a-and-nbsp-a-href-http-investor-biospace-com-engine-account-biospac/#:~:text=Tamiflu%2C%20the%20only%20oral%20antiviral,licensed%20to%20Roche%20in%201996.
I personally want to see a Michael Jackson crotch grab on the way out.
You posted faster than I could :) Unblinding and reporting are two different things. Would be great to have results 'read' today but I'm doubtful.
Not saying this will happen any time soon, but it's possible that a new CEO comes in if/when approval comes. Not a knock against NP cause I'm in agreement with most here that he is the core reason we are even discussing Cytodyn. But, it may require a seasoned professional with industry ties and knowledge of how to run a company up to and after launch. Again, I have high respect for NP but there may come a time to ask him to step aside. I only say this now because I don't want there to be all the crazy speculation about why-----it's irrelevant, it's just the need to have someone who can navigate the waters more effectively.
I logged on early and it seems like this platform is just a production line and they are trying to get through every company's update ASAP, very rushed .
How do you know? Or is this just your own assumption? Just curious.
Not sure about how/when clinical trials can re-start after stopping( funding is always a concern), but as for relisting take a look at this SEC page and go from there. There's a link to all exchanges that fall under the SEC's purview along with their listing requirements.
I'm guessing not a simple task.
https://www.investor.gov/introduction-investing/investing-basics/glossary/listing-standards
My hope is that CYDY enters into licensing agreement with BP whereby we get large upfront payment, milestone payments until approval, and lucrative royalty for all Leron sales globally---but only for Covid. Use this money to continue HIV/Cancer research as well as other indications.
No to mention, whoever our distributor is in the US will be warehousing these vials and distributing. So in case of unforeseen disruption, distributor( McKesson, AmerisourceB, Cardinal, etc)will have inventory to tap into while the disruption is fixed or secondary CMO comes online.
Couldn't agree with you more. And let's not forget investors in lifescience companies are easily manipulated when talking about clinical trial outcomes. Easy to try and poke holes in study design/enrollment/etc but in the end it's about the results---so longs need to hold the line and not forget why you bought into this company in the first place. It's the science and potential to save lives. In my mind CVD 19 was an unexpected event both for victims and for potential treatments---I was invested in this company long before Covid.
Like you, I bought in because of the other indications leron can treat. This company has a lot going for it which outweighs some erroneous content or content taken out of context being published out there.
I'm thinking we'll be bought before it get's to the higher levels---which isn't a bad thing depending on the price.
orange is the new green Danny Boy.
That or teach a course on effective public relations---how to release fake press releases on bogus claims.
DM can teach prisoners how to invest into the biotech/pharma industry, maybe shave some time off his sentence.
That video never gets old. It's also symbolic in that Bob's Big Boy doesn't know when to leave ---as was the case when running(ruining) CVBT.
Yes my shares are now under Venturis too.
I didn't ask my question from a cynical point of view, I was just curious to know what VT has that could contribute to the fight against CVD 19.
Interesting, just curious what they have in their arsenal that would help with CVD 19? Thank you.
I don't hold Seeking Alpha articles in high regard anyway, not that it is important for our current discussion but I saw that it was mentioned.
https://www.forbes.com/sites/richardlevick/2018/08/20/does-seeking-alpha-enable-anonymous-authors-to-spread-fake-news/#1e701d946f47
Loooked to me like she was doodling on the paper in front of her. LOL.
That video is AWESOME!!
I hear rumors Dan and Erik Estrada are gong into a partnership to sell timeshare deals in Guyana --given Erik's expertise on selling land to seniors and Dan's biopharma investing and fundraising with seniors---should be a hit.
It's happening....
(filed: 02/03/2020)
Amended Supplement in support of motion for award under 11 USC 303(i) with Certificate of Service Filed by FRANKLIN L. BROYLES on behalf of CARDIOVASCULAR BIOTHERAPEUTICS, INC. (Related document(s)[166] Motion for Damages for Creditor Misconduct filed by Alleged Debtor CARDIOVASCULAR BIOTHERAPEUTICS, INC.)